Cipher Pharmaceuticals Inc. (FRA:PHE)

Market Cap	229.51M -1.8%
Revenue (ttm)	42.66M +89.2%
Net Income	14.80M +9.5%
EPS	0.57 +5.8%
Shares Out	n/a
PE Ratio	15.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	75
Open	8.75
Previous Close	8.90
Day's Range	8.75 - 9.00
52-Week Range	6.85 - 10.40
Beta	n/a
RSI	47.14
Earnings Date	Mar 20, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PHE

Financial Performance

In 2024, Cipher Pharmaceuticals's revenue was $33.36 million, an increase of 57.66% compared to the previous year's $21.16 million. Earnings were $11.55 million, a decrease of -43.36%.

Financial numbers in USD